SABCS 2021 | TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancer

Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the updated results from TROPION-PanTumor01 (NCT03401385), a Phase I study evaluating datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. Dato-DXd was demonstrated promising antitumor activity with a manageable safety profile in patients with previously treated advanced/metastatic triple-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.